GlassScriptPhysician profile
Sridhar Rao
NPI 1023110780
$1,205.30
in general payments reported to CMS, 2019-2025
16 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.90 · 2024: $741 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.57 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $183.82 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $114.71 | 2024-2025 | Voquezna |
| Amgen INC. | $98.63 | 2024-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $71.99 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $55.46 | 2024-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $45.88 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $40.72 | 2019-2025 | |
| Lilly USA, LLC | $35.08 | 2024 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.51 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $30.66 | 2024 | Auvelity |
| Sanofi-Aventis U.S. LLC | $22.43 | 2024 | |
| Collegium Pharmaceutical, INC. | $21.64 | 2025 | Jornay Pm |
| Cequr Corporation | $19.17 | 2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.19 | 2024 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.84 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridhar Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.